| Journal of Assisted Reproduction and Genetics | 65.6 | 2 | 2 |
| Prelude Fertility | 62.7 | 3 | 1 |
| Pacific Fertility Center Los Angeles (PFCLA) | 62.7 | 3 | 1 |
| Information Retrieval | 60.0 | 6 | 0 |
| Inflammopharmacology | 60.0 | 6 | 0 |
| Mayo Clinic | 49.6 | 4 | 0 |
| Journal of the American Society for Mass Spectrometry | 49.6 | 4 | 0 |
| Cleveland Clinic | 49.6 | 4 | 0 |
| Rice | 49.6 | 4 | 0 |
| Amino Acids | 49.6 | 4 | 0 |
| Human Resource Management Review | 49.6 | 4 | 0 |
| National Institute for Occupational Safety and Health | 42.7 | 3 | 0 |
| Brain and Language | 42.7 | 3 | 0 |
| Algebra Universalis | 42.7 | 3 | 0 |
| The International Journal of African Historical Studies | 42.7 | 3 | 0 |
| JOM | 42.7 | 3 | 0 |
| Virology | 42.7 | 3 | 0 |
| The AAPS Journal | 42.7 | 3 | 0 |
| Aequationes Mathematicae | 42.7 | 3 | 0 |
| Applied Mathematics and Computation | 42.7 | 3 | 0 |
| Fertility and Sterility | 42.7 | 3 | 0 |
| Advances in Virus Research | 42.7 | 3 | 0 |
| Neural Development | 42.7 | 3 | 0 |
| Advances in Parasitology | 42.7 | 3 | 0 |
| Vital and health statistics. Series 21, Data on natality, marriage, and divorce | 42.7 | 3 | 0 |
| Vital and health statistics. Series 5, Comparative international vital and health statistics reports | 42.7 | 3 | 0 |
| EURO Journal on Computational Optimization | 42.7 | 3 | 0 |
| Pacific Fertility Center | 42.7 | 3 | 0 |
| Chronic Diseases and Translational Medicine | 42.7 | 3 | 0 |
| World Journal of Otorhinolaryngology-Head and Neck Surgery | 42.7 | 3 | 0 |
| Recherche - Transports - Securite | 42.7 | 3 | 0 |
| Office of Readiness and Response | 42.7 | 3 | 0 |
| Challenges and strategies in building a foundational digital health data integration ecosystem: a systematic review and thematic synthesis | 42.7 | 3 | 0 |
| fertility clinic | 40.0 | 0 | 3 |
| What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation? | 40.0 | 0 | 3 |
| Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction. | 40.0 | 0 | 3 |
| Ovarian tissue cryopreservation followed by controlled ovarian stimulation and pick-up of mature oocytes does not impair the number or quality of retrieved oocytes | 40.0 | 0 | 3 |
| Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone | 40.0 | 0 | 3 |
| Comparison of anti-mullerian hormone and antral follicle count for assessment of ovarian reserve | 40.0 | 0 | 3 |
| Anti-mullerian hormone and antral follicle count as predictors of ovarian response in assisted reproduction | 40.0 | 0 | 3 |
| The correlation of the antral follicle count and Serum anti-mullerian hormone | 40.0 | 0 | 3 |
| Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy | 40.0 | 0 | 3 |
| In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. | 40.0 | 0 | 3 |
| Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials | 40.0 | 0 | 3 |
| Fertility preservation by ovarian stimulation and oocyte cryopreservation in a 14-year-old adolescent with Turner syndrome mosaicism and impending premature ovarian failure | 40.0 | 0 | 3 |
| Effect of embryo freezing on perinatal outcome after assisted reproduction techniques: lessons from the Latin American Registry of Assisted Reproduction | 40.0 | 0 | 3 |
| Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen | 40.0 | 0 | 3 |
| Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation | 40.0 | 0 | 3 |
| Predicting ovarian reserve and reproductive outcome using antimüllerian hormone (AMH) and antral follicle count (AFC) in patients with previous assisted reproduction technique (ART) failure | 40.0 | 0 | 3 |
| Selection of ovarian stimulation protocol is related to IVF treatment outcome in women 35 years of age and older | 40.0 | 0 | 3 |
| Luteal-phase ovarian stimulation increases the number of mature oocytes in older women with severe diminished ovarian reserve | 40.0 | 0 | 3 |
| Trust women to choose: a response to John a Robertson's 'Egg freezing and Egg banking: empowerment and alienation in assisted reproduction'. | 40.0 | 0 | 3 |
| Fertility preservation with random-start controlled ovarian stimulation and embryo cryopreservation for early pregnancy-associated breast cancer | 40.0 | 0 | 3 |
| Laparoscopic Ovarian Cystectomy of Endometrioma vs Deroofing and Ovarian Reserve | 40.0 | 0 | 3 |
| Anti-Mullerian Hormone (AMH) Versus Antral Follicle Count (AFC) Guided rFSH Dosing Study | 40.0 | 0 | 3 |
| Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients | 40.0 | 0 | 3 |
| Egg Freezing Pilot Study | 40.0 | 0 | 3 |
| Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer | 40.0 | 0 | 3 |
| Fertility preservation in breast cancer patients by embryo cryopreservation after ovarian stimulation with letrozole and FSH | 40.0 | 0 | 3 |
| Role of baseline antral follicle count and anti-Mullerian hormone in the index stimulation cycle of IVF treatment in predicting outcome of subsequent frozen-thawed embryo transfers | 40.0 | 0 | 3 |
| Can delivery mode influence future ovarian reserve? Anti-Mullerian hormone levels and antral follicle count following cesarean section: a prospective cohort study | 40.0 | 0 | 3 |
| Effectiveness of the flexible progestin primed ovarian stimulation protocol compared to the flexible GnRH antagonist protocol in women with decreased ovarian reserve | 40.0 | 0 | 3 |
| Anti-mullerian hormone level as a predictor of ovarian reserve in patients seeking fertility preservation versus infertility treatment | 40.0 | 0 | 3 |
| Antral Follicle Count and AMH Level for Ovarian Reserve Comparison | 40.0 | 0 | 3 |
| Wave Motion | 33.9 | 2 | 0 |
| Ultrasonics Sonochemistry | 33.9 | 2 | 0 |
| Nucleic Acids Research | 33.9 | 2 | 0 |
| Q186756 | 33.9 | 2 | 0 |
| Newsweek | 33.9 | 2 | 0 |
| Q229883 | 33.9 | 2 | 0 |
| Clinical Genitourinary Cancer | 33.9 | 2 | 0 |
| Journal of Economic Theory | 33.9 | 2 | 0 |
| Blood | 33.9 | 2 | 0 |
| Tetrahedron Letters | 33.9 | 2 | 0 |
| Nuclear Physics | 33.9 | 2 | 0 |
| In Vitro Cellular & Developmental Biology - Animal | 33.9 | 2 | 0 |
| Trends in Cell Biology | 33.9 | 2 | 0 |
| Intelligence | 33.9 | 2 | 0 |
| International Journal of Computer Vision | 33.9 | 2 | 0 |
| Journal of Operations Management | 33.9 | 2 | 0 |
| Inflammation Research | 33.9 | 2 | 0 |
| Brachytherapy | 33.9 | 2 | 0 |
| Mechanisms of Ageing and Development | 33.9 | 2 | 0 |
| Trends in Cardiovascular Medicine | 33.9 | 2 | 0 |
| Seminars in Cancer Biology | 33.9 | 2 | 0 |
| Journal of Crystal Growth | 33.9 | 2 | 0 |
| Nanoscale Research Letters | 33.9 | 2 | 0 |
| Field Crops Research | 33.9 | 2 | 0 |
| Cardiovascular Pathology | 33.9 | 2 | 0 |
| Biophysical Journal | 33.9 | 2 | 0 |
| Physica C | 33.9 | 2 | 0 |
| Computer Communications | 33.9 | 2 | 0 |
| Robotics and Autonomous Systems | 33.9 | 2 | 0 |
| Marine Micropaleontology | 33.9 | 2 | 0 |
| Comptes Rendus. Biologies | 33.9 | 2 | 0 |
| Journal of Cardiovascular Magnetic Resonance | 33.9 | 2 | 0 |
| Journal of Electronic Materials | 33.9 | 2 | 0 |
| Mathematical Biosciences | 33.9 | 2 | 0 |
| International Journal of Medical Informatics | 33.9 | 2 | 0 |
| Postharvest Biology and Technology | 33.9 | 2 | 0 |
| Nuclear Physics A | 33.9 | 2 | 0 |
| Insectes Sociaux | 33.9 | 2 | 0 |
| Toxicological Sciences | 33.9 | 2 | 0 |
| Toxicology and Applied Pharmacology | 33.9 | 2 | 0 |
| Advances in Agronomy | 33.9 | 2 | 0 |
| Cancer Detection and Prevention | 33.9 | 2 | 0 |
| Cancer Radiothérapie | 33.9 | 2 | 0 |
| Epi Info | 33.9 | 2 | 0 |
| Microelectronic Engineering | 33.9 | 2 | 0 |
| Optical Switching and Networking | 33.9 | 2 | 0 |
| Journal of Communication Disorders | 33.9 | 2 | 0 |
| Agricultural Systems | 33.9 | 2 | 0 |
| Applied Catalysis A: General | 33.9 | 2 | 0 |
| Applied Clay Science | 33.9 | 2 | 0 |
| International Review of Cytology | 33.9 | 2 | 0 |
| International Journal of Obstetric Anesthesia | 33.9 | 2 | 0 |
| Nuclear Physics B | 33.9 | 2 | 0 |
| Memoirs of the New York Botanical Garden | 33.9 | 2 | 0 |
| Annales pharmaceutiques françaises | 33.9 | 2 | 0 |
| Coordination Chemistry Reviews | 33.9 | 2 | 0 |
| Food Chemistry | 33.9 | 2 | 0 |
| Journal of Molecular Structure | 33.9 | 2 | 0 |
| Electrochemistry Communications | 33.9 | 2 | 0 |
| Fuel Processing Technology | 33.9 | 2 | 0 |
| Advances in Cancer Research | 33.9 | 2 | 0 |
| Journal of Fluorine Chemistry | 33.9 | 2 | 0 |
| Journal of Pharmaceutical Sciences | 33.9 | 2 | 0 |
| Microporous and Mesoporous Materials | 33.9 | 2 | 0 |
| Progress in Solid State Chemistry | 33.9 | 2 | 0 |
| Radiation Physics and Chemistry | 33.9 | 2 | 0 |
| Vibrational Spectroscopy | 33.9 | 2 | 0 |
| Physiology & Behavior | 33.9 | 2 | 0 |
| Plasmonics | 33.9 | 2 | 0 |
| Vacuum | 33.9 | 2 | 0 |
| Zoomorphology | 33.9 | 2 | 0 |
| Computers and Electronics in Agriculture | 33.9 | 2 | 0 |
| Acta Applicandae Mathematicae | 33.9 | 2 | 0 |
| Advances in Applied Clifford Algebras | 33.9 | 2 | 0 |
| Advances in Mathematics | 33.9 | 2 | 0 |
| American Journal of Preventive Medicine | 33.9 | 2 | 0 |
| American Journal of Translational Research | 33.9 | 2 | 0 |
| Archiv der Mathematik | 33.9 | 2 | 0 |
| Archival Science | 33.9 | 2 | 0 |
| Biomedical Optics Express | 33.9 | 2 | 0 |
| Boston University College of General Studies | 33.9 | 2 | 0 |
| Brain Research | 33.9 | 2 | 0 |
| Cellular and Molecular Life Sciences | 33.9 | 2 | 0 |
| China Economic Review | 33.9 | 2 | 0 |
| Chinese Annals of Mathematics, Series B | 33.9 | 2 | 0 |
| Clarion | 33.9 | 2 | 0 |
| Cultural Diversity and Ethnic Minority Psychology | 33.9 | 2 | 0 |
| dbSNP | 33.9 | 2 | 0 |
| Early Childhood Research Quarterly | 33.9 | 2 | 0 |
| Experimental Hematology | 33.9 | 2 | 0 |
| Geochimica et Cosmochimica Acta | 33.9 | 2 | 0 |
| Geometric and Functional Analysis | 33.9 | 2 | 0 |
| Historically Speaking | 33.9 | 2 | 0 |
| Journal of Genetic Counseling | 33.9 | 2 | 0 |
| Journal of Memory and Language | 33.9 | 2 | 0 |
| Journal of Second Language Writing | 33.9 | 2 | 0 |
| Journal of Sound and Vibration | 33.9 | 2 | 0 |
| Journal of the Academy of Nutrition and Dietetics | 33.9 | 2 | 0 |
| Laboratory Investigation | 33.9 | 2 | 0 |
| Learning and Individual Differences | 33.9 | 2 | 0 |
| Magnetic Resonance Imaging | 33.9 | 2 | 0 |
| Museum Management and Curatorship | 33.9 | 2 | 0 |
| Personality and Individual Differences | 33.9 | 2 | 0 |
| Preventing Chronic Disease | 33.9 | 2 | 0 |
| Quaternary Research | 33.9 | 2 | 0 |
| Western Journal of Medicine | 33.9 | 2 | 0 |
| Society | 33.9 | 2 | 0 |
| Stem Cell Reviews and Reports | 33.9 | 2 | 0 |
| The Journal of Supercomputing | 33.9 | 2 | 0 |
| Transplantation Proceedings | 33.9 | 2 | 0 |
| Trends in Amplification | 33.9 | 2 | 0 |
| Ulster Medical Journal | 33.9 | 2 | 0 |
| Zeitschrift fuer Angewandte Mathematik und Physik | 33.9 | 2 | 0 |
| Molecules and Cells | 33.9 | 2 | 0 |
| Finite Elements in Analysis and Design | 33.9 | 2 | 0 |
| Linear Algebra and its Applications | 33.9 | 2 | 0 |
| Nonlinear Differential Equations and Applications | 33.9 | 2 | 0 |
| Annales de l'Institut Henri Poincare C | 33.9 | 2 | 0 |
| Annals of Combinatorics | 33.9 | 2 | 0 |
| Applied Mathematics Letters | 33.9 | 2 | 0 |
| Applied Numerical Mathematics | 33.9 | 2 | 0 |
| Current Opinion in Genetics & Development | 33.9 | 2 | 0 |
| Journal of Fluency Disorders | 33.9 | 2 | 0 |
| Nonlinear Analysis | 33.9 | 2 | 0 |
| Nuclear Instruments & Methods in Physics Research B | 33.9 | 2 | 0 |
| Seminars in Cell & Developmental Biology | 33.9 | 2 | 0 |
| Systems & Control Letters | 33.9 | 2 | 0 |
| NeuroToxicology | 33.9 | 2 | 0 |
| Calcolo | 33.9 | 2 | 0 |
| Complex Analysis and Operator Theory | 33.9 | 2 | 0 |
| Differential Geometry and its Applications | 33.9 | 2 | 0 |
| Botanica Helvetica | 33.9 | 2 | 0 |
| Journal of Combinatorial Theory, Series B | 33.9 | 2 | 0 |
| Journal of Fixed Point Theory and Applications | 33.9 | 2 | 0 |
| Journal of Geometric Analysis | 33.9 | 2 | 0 |
| Journal of Mathematical Analysis and Applications | 33.9 | 2 | 0 |
| Positivity | 33.9 | 2 | 0 |
| Revista de la Real Academia de Ciencias Exactas, Físicas y Naturales. Serie A. Matemáticas | 33.9 | 2 | 0 |
| Journal of Web Semantics | 33.9 | 2 | 0 |
| Pathophysiology | 33.9 | 2 | 0 |
| BJOG: an International Journal of Obstetrics and Gynaecology | 33.9 | 2 | 0 |
| Current Hypertension Reports | 33.9 | 2 | 0 |
| Archives of Gerontology and Geriatrics | 33.9 | 2 | 0 |
| Cryptogamie Bryologie | 33.9 | 2 | 0 |
| Advances in Marine Biology | 33.9 | 2 | 0 |
| BBA: Molecular Basis of Disease | 33.9 | 2 | 0 |
| Global Finance Journal | 33.9 | 2 | 0 |
| Advances in Carbohydrate Chemistry and Biochemistry | 33.9 | 2 | 0 |
| Acta Metallurgica Sinica | 33.9 | 2 | 0 |
| Journal of Geometry | 33.9 | 2 | 0 |
| AAPS PharmSciTech | 33.9 | 2 | 0 |
| Brain and Development | 33.9 | 2 | 0 |
| Cryptogamie Algologie | 33.9 | 2 | 0 |
| Aggression and Violent Behavior | 33.9 | 2 | 0 |
| Neuropsychiatrie | 33.9 | 2 | 0 |
| Pediatric Neurology | 33.9 | 2 | 0 |
| General Hospital Psychiatry | 33.9 | 2 | 0 |
| Current Topics in Microbiology and Immunology | 33.9 | 2 | 0 |
| Comparative Immunology, Microbiology & Infectious Diseases | 33.9 | 2 | 0 |
| Pure and Applied Geophysics | 33.9 | 2 | 0 |
| International Journal of Mental Health Systems | 33.9 | 2 | 0 |
| International Journal of Mental Health and Addiction | 33.9 | 2 | 0 |
| Advances in Applied Microbiology | 33.9 | 2 | 0 |
| Accreditation and Quality Assurance | 33.9 | 2 | 0 |
| Optometry - Journal of the American Optometric Association | 33.9 | 2 | 0 |
| Academic Psychiatry | 33.9 | 2 | 0 |
| Journal of Policy Modeling | 33.9 | 2 | 0 |
| Archives of Women's Mental Health | 33.9 | 2 | 0 |
| Best Practice and Research: Clinical Gastroenterology | 33.9 | 2 | 0 |
| International Journal of Law and Psychiatry | 33.9 | 2 | 0 |
| Prostaglandins and Other Lipid Mediators | 33.9 | 2 | 0 |
| Building and Environment | 33.9 | 2 | 0 |
| Computational Complexity | 33.9 | 2 | 0 |
| Industrial Marketing Management | 33.9 | 2 | 0 |
| Science and Engineering Ethics | 33.9 | 2 | 0 |
| New Zealand Journal of Educational Studies | 33.9 | 2 | 0 |
| Meat Science | 33.9 | 2 | 0 |
| Research in Organizational Behavior | 33.9 | 2 | 0 |
| Fish and Shellfish Immunology | 33.9 | 2 | 0 |
| Journal of Physiological Anthropology | 33.9 | 2 | 0 |
| Journal of Immunological Methods | 33.9 | 2 | 0 |
| The Behavior Analyst | 33.9 | 2 | 0 |
| Iranian Journal of Science and Technology Transaction A: Science | 33.9 | 2 | 0 |
| Human Pathology | 33.9 | 2 | 0 |
| Mathematics in Computer Science | 33.9 | 2 | 0 |
| Journal of Infection and Chemotherapy | 33.9 | 2 | 0 |
| Boston University Law Review | 33.9 | 2 | 0 |
| Comparative Biochemistry and Physiology. Part A: Molecular and Integrative Physiology | 33.9 | 2 | 0 |
| The History of the Family | 33.9 | 2 | 0 |
| Journal of Behavioral Health Services and Research | 33.9 | 2 | 0 |
| Journal of Environmental Management | 33.9 | 2 | 0 |
| Insight | 33.9 | 2 | 0 |
| Business Horizons | 33.9 | 2 | 0 |
| Addiction Science and Clinical Practice | 33.9 | 2 | 0 |
| Computers in Human Behavior | 33.9 | 2 | 0 |
| Government Information Quarterly | 33.9 | 2 | 0 |
| Linguistics and Education | 33.9 | 2 | 0 |
| International Journal of Artificial Intelligence in Education | 33.9 | 2 | 0 |
| Cryptogamie Mycologie | 33.9 | 2 | 0 |
| Behaviour Research and Therapy | 33.9 | 2 | 0 |
| Advances in Botanical Research | 33.9 | 2 | 0 |
| Journal of the Korean Statistical Society | 33.9 | 2 | 0 |
| Journal of Urban Health | 33.9 | 2 | 0 |
| Annals of Biomedical Engineering | 33.9 | 2 | 0 |
| Archivum Immunologiae et Therapiae Experimentalis | 33.9 | 2 | 0 |
| Aquatic Sciences | 33.9 | 2 | 0 |
| Comptes Rendus. Géoscience | 33.9 | 2 | 0 |
| Physics in Perspective | 33.9 | 2 | 0 |
| Journal of Mathematical Fluid Mechanics | 33.9 | 2 | 0 |
| Socio-Economic Planning Sciences | 33.9 | 2 | 0 |
| Sports Medicine | 33.9 | 2 | 0 |
| The Journal of Science and Technology Law | 33.9 | 2 | 0 |
| Chemoecology | 33.9 | 2 | 0 |
| Software Quality Journal | 33.9 | 2 | 0 |
| Organizational Dynamics | 33.9 | 2 | 0 |
| The American Journal of Surgery | 33.9 | 2 | 0 |
| Reproductive Medicine and Biology | 33.9 | 2 | 0 |
| Neurological Sciences | 33.9 | 2 | 0 |
| Psychonomic Bulletin and Review | 33.9 | 2 | 0 |
| Clinical Neurophysiology | 33.9 | 2 | 0 |
| International Urology and Nephrology | 33.9 | 2 | 0 |
| Ocean Engineering | 33.9 | 2 | 0 |
| International Review of Law and Economics | 33.9 | 2 | 0 |
| Journal of Gastrointestinal Surgery | 33.9 | 2 | 0 |
| Journal of Children's Orthopaedics | 33.9 | 2 | 0 |
| Nuclear Physics B - Proceedings Supplements | 33.9 | 2 | 0 |
| Indian Journal of International Law | 33.9 | 2 | 0 |
| Revue Europeene de Psychologie Appliquee | 33.9 | 2 | 0 |
| Computers & Graphics | 33.9 | 2 | 0 |
| Journal of African Earth Sciences | 33.9 | 2 | 0 |
| Journal of the Society of Laparoendoscopic Surgeons | 33.9 | 2 | 0 |
| Annual Reports in Medicinal Chemistry | 33.9 | 2 | 0 |
| Comparative Biochemistry and Physiology. Part D: Genomics and Proteomics | 33.9 | 2 | 0 |
| European Journal of Mechanics A - Solids | 33.9 | 2 | 0 |
| Computers and Composition | 33.9 | 2 | 0 |
| Annals of Hematology | 33.9 | 2 | 0 |
| Review of Financial Economics | 33.9 | 2 | 0 |
| Maturitas | 33.9 | 2 | 0 |
| Structure and Bonding | 33.9 | 2 | 0 |
| Financial Services Review | 33.9 | 2 | 0 |
| Mechanics Research Communications | 33.9 | 2 | 0 |
| Knowledge and Information Systems | 33.9 | 2 | 0 |
| Operations Management Research | 33.9 | 2 | 0 |
| Journal of Cultural Heritage | 33.9 | 2 | 0 |
| Clinical Imaging | 33.9 | 2 | 0 |
| Journal of Environmental Sciences | 33.9 | 2 | 0 |
| Journal of Clinical Lipidology | 33.9 | 2 | 0 |
| Journal of Orthopaedics, Trauma and Rehabilitation | 33.9 | 2 | 0 |
| Ticks and Tick-borne Diseases | 33.9 | 2 | 0 |
| The Electricity Journal | 33.9 | 2 | 0 |
| Social Science Research | 33.9 | 2 | 0 |
| Archives of Cardiovascular Diseases Supplements | 33.9 | 2 | 0 |
| Fluids and Barriers of the CNS | 33.9 | 2 | 0 |
| National Survey of Family Growth | 33.9 | 2 | 0 |
| National Vital Statistics System | 33.9 | 2 | 0 |
| NIOSH Power Tools Database | 33.9 | 2 | 0 |
| UCLA Health System | 33.9 | 2 | 0 |
| Lecture Notes in Mathematics | 33.9 | 2 | 0 |
| Journal on Data Semantics | 33.9 | 2 | 0 |
| Q20641742 | 33.9 | 2 | 0 |
| Advances in Nutrition | 33.9 | 2 | 0 |
| Oregon Graduate Center | 33.9 | 2 | 0 |
| Zeitschrift für Weiterbildungsforschung - Report | 33.9 | 2 | 0 |
| Morbidity and Mortality Weekly Report: Recommendations and Reports | 33.9 | 2 | 0 |
| Current Environmental Health Reports | 33.9 | 2 | 0 |
| Filtration & Separation | 33.9 | 2 | 0 |
| Fundamental and Applied Toxicology | 33.9 | 2 | 0 |
| Journal of the Less Common Metals | 33.9 | 2 | 0 |
| Scripta Metallurgica | 33.9 | 2 | 0 |
| SpringerPlus | 33.9 | 2 | 0 |
| Current Psychiatry Reports | 33.9 | 2 | 0 |
| Diseases of the chest | 33.9 | 2 | 0 |
| Chemical health & safety American Chemical Society, Division of Chemical Health and Safety | 33.9 | 2 | 0 |
| Virologica Sinica | 33.9 | 2 | 0 |
| Revista paulista de pediatria : orgão oficial da Sociedade de Pediatria de São Paulo | 33.9 | 2 | 0 |
| The Analysis of verbal behavior | 33.9 | 2 | 0 |
| Behavior analysis in practice | 33.9 | 2 | 0 |
| Behavioral Biology | 33.9 | 2 | 0 |
| The Journal of clinical and aesthetic dermatology | 33.9 | 2 | 0 |
| Current infectious disease reports | 33.9 | 2 | 0 |
| Alcohol research : current reviews | 33.9 | 2 | 0 |
| Cell Biology International Reports | 33.9 | 2 | 0 |
| Current HIV/AIDS Reports | 33.9 | 2 | 0 |
| Vital & health statistics. Series 3, Analytical and epidemiological studies | 33.9 | 2 | 0 |
| Current heart failure reports | 33.9 | 2 | 0 |
| The Ultrasound Journal | 33.9 | 2 | 0 |
| Dermato-endocrinology | 33.9 | 2 | 0 |
| British Heart Journal | 33.9 | 2 | 0 |
| The western journal of emergency medicine | 33.9 | 2 | 0 |
| Hepatology international | 33.9 | 2 | 0 |
| Prostate international | 33.9 | 2 | 0 |
| Psychiatry | 33.9 | 2 | 0 |
| Journal of ultrasound | 33.9 | 2 | 0 |
| Mycobiology | 33.9 | 2 | 0 |
| The Lancet Psychiatry | 33.9 | 2 | 0 |
| Advances in food research | 33.9 | 2 | 0 |
| Science in China. Series B, Chemistry, life sciences & earth sciences | 33.9 | 2 | 0 |
| Genetic analysis, techniques and applications | 33.9 | 2 | 0 |
| Journal of the American Pharmaceutical Association | 33.9 | 2 | 0 |
| Vital and health statistics. Series 3, Analytical studies | 33.9 | 2 | 0 |
| Vital and health statistics. Ser. 4, Documents and committee reports | 33.9 | 2 | 0 |
| Vital and health statistics. Series 13, Data from the National Health Survey | 33.9 | 2 | 0 |
| Journal of agricultural ethics | 33.9 | 2 | 0 |
| Journal of epilepsy | 33.9 | 2 | 0 |
| Ethology and sociobiology | 33.9 | 2 | 0 |
| Aging trends (Hyattsville, Md.) | 33.9 | 2 | 0 |
| Clinical microbiology newsletter | 33.9 | 2 | 0 |
| Journal of the American Aging Association | 33.9 | 2 | 0 |
| NCHS data brief | 33.9 | 2 | 0 |
| European geriatric medicine | 33.9 | 2 | 0 |
| Clinical journal of gastroenterology | 33.9 | 2 | 0 |
| Cardiovascular intervention and therapeutics | 33.9 | 2 | 0 |
| Journal of Verbal Learning and Verbal Behavior | 33.9 | 2 | 0 |
| Paediatrics and Child Health | 33.9 | 2 | 0 |
| International journal of multimedia information retrieval | 33.9 | 2 | 0 |
| Urolithiasis | 33.9 | 2 | 0 |
| Network modeling and analysis in health informatics and bioinformatics | 33.9 | 2 | 0 |
| The Journal of frailty & aging | 33.9 | 2 | 0 |
| Alpine botany | 33.9 | 2 | 0 |
| The Lancet: Diabetes & Endocrinology | 33.9 | 2 | 0 |
| Social Network Analysis and Mining | 33.9 | 2 | 0 |
| Medical science educator | 33.9 | 2 | 0 |
| Pastoralism : research, policy and practice | 33.9 | 2 | 0 |
| Life sciences, society and policy | 33.9 | 2 | 0 |
| Boletin de la Sociedad Matematica Mexicana | 33.9 | 2 | 0 |
| Avian Research | 33.9 | 2 | 0 |
| Alzheimer's & dementia (Amsterdam, Netherlands) | 33.9 | 2 | 0 |
| Journal of experimental orthopaedics | 33.9 | 2 | 0 |
| Sports medicine - open | 33.9 | 2 | 0 |
| Journal of psychosocial rehabilitation and mental health | 33.9 | 2 | 0 |
| Materials for renewable and sustainable energy | 33.9 | 2 | 0 |
| Cell Chemical Biology | 33.9 | 2 | 0 |
| MMWR supplements | 33.9 | 2 | 0 |
| Clinical neurophysiology practice | 33.9 | 2 | 0 |
| Journal of pseudo-differential operators and applications | 33.9 | 2 | 0 |
| Information and control | 33.9 | 2 | 0 |
| Studies in Logic and the Foundations of Mathematics | 33.9 | 2 | 0 |
| Computing systems in engineering : an international journal | 33.9 | 2 | 0 |
| National Center for Emerging and Zoonotic Infectious Diseases | 33.9 | 2 | 0 |
| Division of Parasitic Diseases and Malaria | 33.9 | 2 | 0 |
| Chronic Disease Prevention and Health Promotion | 33.9 | 2 | 0 |
| Colorado Center for Reproductive Medicine | 33.9 | 2 | 0 |
| Shady Grove Fertility Center | 33.9 | 2 | 0 |
| Cooper Health System | 33.9 | 2 | 0 |
| EURO Journal on Transportation and Logistics | 33.9 | 2 | 0 |
| Baylor Scott & White Health | 33.9 | 2 | 0 |
| Theoretical Biology | 33.9 | 2 | 0 |
| KI – Künstliche Intelligenz | 33.9 | 2 | 0 |
| Studies in Big Data | 33.9 | 2 | 0 |
| The Journal of Finance and Data Science | 33.9 | 2 | 0 |
| Fertility Centers of Illinois | 33.9 | 2 | 0 |
| New Hope Fertility Center | 33.9 | 2 | 0 |
| Pacific Centre for Reproductive Medicine | 33.9 | 2 | 0 |
| Johns Hopkins Medicine | 33.9 | 2 | 0 |
| Journal für Urologie und Urogynäkologie Österreich | 33.9 | 2 | 0 |
| International Journal of Euro-Mediterranean Studies | 33.9 | 2 | 0 |
| Journal of Palaeogeography | 33.9 | 2 | 0 |
| Journal of Basic and Applied Zoology | 33.9 | 2 | 0 |
| Journal of Urban Management | 33.9 | 2 | 0 |
| Journal of Asian Ceramic Societies | 33.9 | 2 | 0 |
| Journal of Modern Power Systems and Clean Energy | 33.9 | 2 | 0 |
| Climate Risk Management | 33.9 | 2 | 0 |
| Information Processing in Agriculture | 33.9 | 2 | 0 |
| Journal of Organization Design | 33.9 | 2 | 0 |
| Advances in Natural Language Processing: 4th International Conference, EsTAL 2004, Alicante, Spain, October 20-22, 2004. Proceedings | 33.9 | 2 | 0 |
| Lecture Notes in Social Networks | 33.9 | 2 | 0 |
| International Journal of Data Science and Analytics | 33.9 | 2 | 0 |
| Advances in Inorganic Chemistry and Radiochemistry | 33.9 | 2 | 0 |
| Fish Physiology | 33.9 | 2 | 0 |
| Computer Vision, Graphics, and Image Processing | 33.9 | 2 | 0 |
| Network Security | 33.9 | 2 | 0 |
| Inorganic and Nuclear Chemistry Letters | 33.9 | 2 | 0 |
| Inorganica Chimica Acta Reviews | 33.9 | 2 | 0 |
| Data Integration in the Life Sciences: 6th International Workshop, DILS 2009, Manchester, UK, July 20-22, 2009. Proceedings | 33.9 | 2 | 0 |
| EURO Journal on Decision Processes | 33.9 | 2 | 0 |
| Information Storage and Retrieval | 33.9 | 2 | 0 |
| Biometric Technology Today | 33.9 | 2 | 0 |
| Membrane Technology | 33.9 | 2 | 0 |
| Automatic Documentation and Mathematical Linguistics | 33.9 | 2 | 0 |
| Evolutionary Psychological Science | 33.9 | 2 | 0 |
| Deutsche Zeitschrift für Akupunktur | 33.9 | 2 | 0 |
| Filtration Industry Analyst | 33.9 | 2 | 0 |
| Fuel Cells Bulletin | 33.9 | 2 | 0 |
| Journal of Patient Safety & Infection Control | 33.9 | 2 | 0 |
| Pump Industry Analyst | 33.9 | 2 | 0 |
| Space Research Today | 33.9 | 2 | 0 |
| World Pumps | 33.9 | 2 | 0 |
| Review Journal of Autism and Developmental Disorders | 33.9 | 2 | 0 |
| Christopher R. Conley | 33.9 | 2 | 0 |
| China population and development studies | 33.9 | 2 | 0 |
| Environment systems & decisions | 33.9 | 2 | 0 |
| Water Security | 33.9 | 2 | 0 |
| Electroencephalography and Clinical Neurophysiology - Evoked Potentials | 33.9 | 2 | 0 |
| Analysis and Mathematical Physics | 33.9 | 2 | 0 |
| Nuclear Data Sheets Section B | 33.9 | 2 | 0 |
| Journal of Education | 33.9 | 2 | 0 |
| Bulletin Volcanologique | 33.9 | 2 | 0 |
| Corporate Environmental Strategy | 33.9 | 2 | 0 |
| Current Paediatrics | 33.9 | 2 | 0 |
| Zeolites | 33.9 | 2 | 0 |
| Controlling & Management | 33.9 | 2 | 0 |
| Heart Rhythm O2 | 33.9 | 2 | 0 |
| International Strategic Management Review | 33.9 | 2 | 0 |
| Systems Engineering - Theory & Practice | 33.9 | 2 | 0 |
| The Journal of the American Dental Association (1922) | 33.9 | 2 | 0 |
| AI-KG: An Automatically Generated Knowledge Graph of Artificial Intelligence | 33.9 | 2 | 0 |
| University of Pennsylvania Division of Endocrinology, Diabetes and Metabolism | 33.9 | 2 | 0 |
| Green Synthesis and Catalysis | 33.9 | 2 | 0 |
| Artificial Intelligence in the Life Sciences | 33.9 | 2 | 0 |
| Healthcare Infection Control Practices Advisory Committee | 33.9 | 2 | 0 |
| Adverse events in cognitive behavioral therapy and relaxation training for children and adolescents with obsessive-compulsive disorder: A mixed methods study and analysis plan for the TECTO trial | 33.9 | 2 | 0 |
| Progyny, Inc. | 33.9 | 2 | 0 |
| Palgrave Studies in New Religions and Alternative Spiritualities | 33.9 | 2 | 0 |
| The Semantic Web – ISWC 2024 23rd International Semantic Web Conference, Baltimore, MD, USA, November 11–15, 2024, Proceedings, Part I | 33.9 | 2 | 0 |
| Radiología (English Edition) | 33.9 | 2 | 0 |
| Building Science | 33.9 | 2 | 0 |
| A Framework for Question Answering on Knowledge Graphs Using Large Language Models | 33.9 | 2 | 0 |
| Q136841101 | 33.9 | 2 | 0 |
| Energy Storage as an Equity Asset | 33.9 | 2 | 0 |
| Q140363295 | 33.9 | 2 | 0 |
| assisted reproductive technology | 31.7 | 0 | 2 |
| Vitrification (ovocytes) | 31.7 | 0 | 2 |
| GoodLeap | 31.7 | 0 | 2 |
| Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction | 31.7 | 0 | 2 |
| Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction | 31.7 | 0 | 2 |
| Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles | 31.7 | 0 | 2 |
| Different ovarian stimulation protocols for women with diminished ovarian reserve | 31.7 | 0 | 2 |
| Journal of Experimental & Clinical Assisted Reproduction: shaping the future of research and practice in reproductive endocrinology/infertility | 31.7 | 0 | 2 |
| Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers | 31.7 | 0 | 2 |
| Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice | 31.7 | 0 | 2 |
| Myocardial infarction complicating the initial phase of an ovarian stimulation protocol | 31.7 | 0 | 2 |
| Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents | 31.7 | 0 | 2 |
| Q28344605 | 31.7 | 0 | 2 |
| Assisted reproduction-in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin-releasing hormone analogues | 31.7 | 0 | 2 |
| Analysis of oocyte cryopreservation in assisted reproduction: the Italian National Register data from 2005 to 2007 | 31.7 | 0 | 2 |
| Follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in assisted reproduction cycles | 31.7 | 0 | 2 |
| Ovarian reserve tests and their utility in predicting response to controlled ovarian stimulation in rhesus monkeys | 31.7 | 0 | 2 |
| Antral follicle count in normal (fertility-proven) and infertile Indian women | 31.7 | 0 | 2 |
| Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles. | 31.7 | 0 | 2 |
| Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature | 31.7 | 0 | 2 |
| Oocyte cryopreservation: a feasible fertility preservation option for reproductive age cancer survivors. | 31.7 | 0 | 2 |
| Assisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011. | 31.7 | 0 | 2 |
| Ovarian response and cumulative live birth rate of women undergoing in-vitro fertilisation who had discordant anti-Mullerian hormone and antral follicle count measurements: a retrospective study. | 31.7 | 0 | 2 |
| Anti-Müllerian Hormone Serum Values and Ovarian Reserve: Can It Predict a Decrease in Fertility after Ovarian Stimulation by ART Cycles? | 31.7 | 0 | 2 |
| Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation | 31.7 | 0 | 2 |
| A minimally monitored assisted reproduction stimulation protocol reduces cost without compromising success | 31.7 | 0 | 2 |
| Embryo cryopreservation in a case of acute promyelocytic leukemia, incidentally diagnosed during ovarian stimulation for in-vitro fertilization | 31.7 | 0 | 2 |
| Anti-Mullerian Hormone: A Marker of Ovarian Reserve and its Association with Polycystic Ovarian Syndrome | 31.7 | 0 | 2 |
| Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction | 31.7 | 0 | 2 |
| Testing for Ovarian Reserve in Assisted Reproduction programs: the current point of view | 31.7 | 0 | 2 |
| Oocyte Cryopreservation for Fertility Preservation in Postpubertal Female Children at Risk for Premature Ovarian Failure Due to Accelerated Follicle Loss in Turner Syndrome or Cancer Treatments | 31.7 | 0 | 2 |
| The impact of endometrioma and laparoscopic cystectomy on ovarian reserve and the exploration of related factors assessed by serum anti-Mullerian hormone: a prospective cohort study | 31.7 | 0 | 2 |
| Role of baseline antral follicle count and anti-Mullerian hormone in prediction of cumulative live birth in the first in vitro fertilisation cycle: a retrospective cohort analysis. | 31.7 | 0 | 2 |
| Pronuclear embryo cryopreservation experience: outcomes for reducing the risk of ovarian hyperstimulation syndrome and for fertility preservation in cancer patients | 31.7 | 0 | 2 |
| Chronological age vs biological age: an age-related normogram for antral follicle count, FSH and anti-Mullerian hormone. | 31.7 | 0 | 2 |
| Comparison of pregnancy outcome after letrozole versus clomiphene treatment for mild ovarian stimulation protocol in poor responders | 31.7 | 0 | 2 |
| Ovarian stimulation in patients with breast cancer | 31.7 | 0 | 2 |
| The correlations of anti-mullerian hormone, follicle-stimulating hormone and antral follicle count in different age groups of infertile women | 31.7 | 0 | 2 |
| Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared to age matched controls: a 17-year experience | 31.7 | 0 | 2 |
| Evidence to Incorporate Inclusive Reproductive Health Measures in Guidelines for Childhood and Adolescent Cancer Survivors | 31.7 | 0 | 2 |
| Choice of ovarian stimulation regimens in assisted reproduction: finding the thread in the gonadotropin maze | 31.7 | 0 | 2 |
| Ovarian stimulation for emergency fertility preservation in cancer patients: A case series study | 31.7 | 0 | 2 |
| The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility | 31.7 | 0 | 2 |
| Optimal timing for elective egg freezing | 31.7 | 0 | 2 |
| Human oocyte cryopreservation: a valid alternative to embryo cryopreservation? | 31.7 | 0 | 2 |
| Oocyte retrieval at 140-mmHg negative aspiration pressure: A promising alternative to flushing and aspiration in assisted reproduction in women with low ovarian reserve | 31.7 | 0 | 2 |
| Ovarian stimulation and embryo banking for fertility preservation in a woman with severe mixed connective tissue disease: is it safe? | 31.7 | 0 | 2 |
| Is ABO blood type associated with ovarian stimulation response in patients with diminished ovarian reserve? | 31.7 | 0 | 2 |
| Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer | 31.7 | 0 | 2 |
| Oocyte versus embryo cryopreservation for fertility preservation in cancer patients: guaranteeing a women's autonomy | 31.7 | 0 | 2 |
| Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation | 31.7 | 0 | 2 |
| The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle: Evidence from a meta-analysis | 31.7 | 0 | 2 |
| Anti-Mullerian hormone as a predictor of ovarian reserve in ART protocols: the hidden role of thyroid autoimmunity | 31.7 | 0 | 2 |
| Outcomes of ovarian stimulation after treatment with chemotherapy | 31.7 | 0 | 2 |
| Use of anti-mullerian hormone for testing ovarian reserve: a survey of 796 infertility clinics worldwide | 31.7 | 0 | 2 |
| Measurement of antral follicle count in patients undergoing in vitro fertilization treatment: results of a worldwide web-based survey | 31.7 | 0 | 2 |
| Follicular fluid insulin-like growth factor-I and insulin-like growth factor-binding protein-1 and -3 vary as a function of ovarian reserve and ovarian stimulation | 31.7 | 0 | 2 |
| Conservative management versus aspiration of functional ovarian cysts before ovarian stimulation for assisted reproduction | 31.7 | 0 | 2 |
| The added value of embryo cryopreservation to cumulative ongoing pregnancy rates per IVF treatment: is cryopreservation worth the effort? | 31.7 | 0 | 2 |
| Mature oocyte retrieval during laparotomic debulking surgery following random-start controlled ovarian stimulation for fertility preservation in a patient with suspected ovarian cancer | 31.7 | 0 | 2 |
| A global perspective on assisted reproductive technology fertility treatment: an 8-country fertility specialist survey | 31.7 | 0 | 2 |
| Anti-mullerian hormone cut-off values for predicting poor ovarian response to exogenous ovarian stimulation in in-vitro fertilization | 31.7 | 0 | 2 |
| Age-Related Normogram for Ovarian Antral Follicle Count in Women with Polycystic Ovary Syndrome and Comparison with Age Matched Controls Using Magnetic Resonance Imaging | 31.7 | 0 | 2 |
| The role of fertility preservation in patients with endometriosis | 31.7 | 0 | 2 |
| Reluctance of medical professionals in adopting natural-cycle and minimal ovarian stimulation protocols in human clinical assisted reproduction | 31.7 | 0 | 2 |
| Random-start controlled ovarian stimulation for emergency fertility preservation in a patient with myelodysplastic syndrome: a case report | 31.7 | 0 | 2 |
| Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies | 31.7 | 0 | 2 |
| Use of letrozole in assisted reproduction: a systematic review and meta-analysis. | 31.7 | 0 | 2 |
| Comparison of the GnRH agonist and antagonist protocol on the same patients in assisted reproduction during controlled ovarian stimulation cycles | 31.7 | 0 | 2 |
| "Anti-Mullerian Hormone: Marker for Ovarian Response in Controlled Ovarian Stimulation for IVF Patients": A First Pilot Study in the Indian Population | 31.7 | 0 | 2 |
| AMH type II receptor and AMH gene polymorphisms are not associated with ovarian reserve, response, or outcomes in ovarian stimulation. | 31.7 | 0 | 2 |
| Egg freezing and egg banking: empowerment and alienation in assisted reproduction | 31.7 | 0 | 2 |
| Determining an anti-mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve | 31.7 | 0 | 2 |
| Assisted reproduction and fertility preservation techniques in cancer patients | 31.7 | 0 | 2 |
| Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles | 31.7 | 0 | 2 |
| Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment | 31.7 | 0 | 2 |
| Anti-Müllerian hormone and antral follicle count reveal a late impairment of ovarian reserve in patients undergoing low-gonadotoxic regimens for hematological malignancies | 31.7 | 0 | 2 |
| Endometrial signaling pathways during ovarian stimulation for assisted reproduction technology | 31.7 | 0 | 2 |
| Twenty-five-year-old Woman with Bilateral Borderline Ovarian Tumour Desiring to Preserve Fertility - Case Report and Literature Review on the Current State of Fertility Preservation in Women with Borderline Ovarian Tumours | 31.7 | 0 | 2 |
| Fertility Preservation Options after Gonadotoxic Chemotherapy | 31.7 | 0 | 2 |
| Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients | 31.7 | 0 | 2 |
| Assessment of ovarian reserve: Anti-Mullerian hormone versus follicle stimulating hormone | 31.7 | 0 | 2 |
| Anti-mullerian hormone as a predictor of ovarian reserve and ovarian response in IVF women from Gaza strip | 31.7 | 0 | 2 |
| Ovarian reserve and subsequent assisted reproduction outcomes after methotrexate therapy for ectopic pregnancy or pregnancy of unknown location | 31.7 | 0 | 2 |
| Current approach to fertility preservation by embryo cryopreservation | 31.7 | 0 | 2 |
| Fertility-Preserving Treatment Options in Patients with Malignant Hematological Diseases | 31.7 | 0 | 2 |
| Clinical recommendation on fertility preservation in borderline ovarian neoplasm: ovarian stimulation and oocyte retrieval after conservative surgery | 31.7 | 0 | 2 |
| The promise of in vitro maturation in assisted reproduction and fertility preservation. | 31.7 | 0 | 2 |
| Oocyte cryopreservation as a fertility preservation measure for cancer patients | 31.7 | 0 | 2 |
| Oocyte cryopreservation for donor egg banking | 31.7 | 0 | 2 |
| Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction | 31.7 | 0 | 2 |
| Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature | 31.7 | 0 | 2 |
| Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer | 31.7 | 0 | 2 |
| Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients | 31.7 | 0 | 2 |
| The effect of surgery for endometrioma on ovarian reserve evaluated by antral follicle count: a systematic review and meta-analysis. | 31.7 | 0 | 2 |
| AMH: An ovarian reserve biomarker in assisted reproduction. | 31.7 | 0 | 2 |
| Shifting Paradigms in Diminished Ovarian Reserve and Advanced Reproductive Age in Assisted Reproduction: Customization Instead of Conformity | 31.7 | 0 | 2 |
| Fertility Preservation in Women with Ovarian Endometriosis | 31.7 | 0 | 2 |
| Molecular aspects and clinical methods for preserving ovarian reserves in women receiving cancer treatment | 31.7 | 0 | 2 |
| What women want? A scoping survey on women's knowledge, attitudes and behaviours towards ovarian reserve testing and egg freezing. | 31.7 | 0 | 2 |
| BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD. | 31.7 | 0 | 2 |
| Ovarian Stimulation Protocol in IVF: An Up-to-Date Review of the Literature | 31.7 | 0 | 2 |
| Anti-Mullerian hormone concentrations in individual follicular fluids within one stimulated IVF cycle resemble blood serum values. | 31.7 | 0 | 2 |
| Urinary triclosan concentrations and diminished ovarian reserve among women undergoing treatment in a fertility clinic | 31.7 | 0 | 2 |
| Oocyte vitrification for elective fertility preservation: the past, present, and future | 31.7 | 0 | 2 |
| Mature Oocyte Cryopreservation for Fertility Preservation | 31.7 | 0 | 2 |
| Assessment of ovarian reserve and fertility preservation strategies in children treated for cancer. | 31.7 | 0 | 2 |
| Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response | 31.7 | 0 | 2 |
| EXPRESSION OF CONCERN: Addition of growth hormone to the microflare stimulation protocol among women with poor ovarian response | 31.7 | 0 | 2 |
| Fertility Preservation Options for Men and Women With Cancer | 31.7 | 0 | 2 |
| The cutoff values of serum AMH levels and starting recFSH doses for the individualization of IVF treatment strategies | 31.7 | 0 | 2 |
| Emergent Oocyte Cryopreservation with a Novel Ovarian Transposition Technique in a Colorectal Cancer Patient: A Combined Approach for Fertility Preservation. A Case Report | 31.7 | 0 | 2 |
| Oocyte cryopreservation for fertility preservation in women with cancer | 31.7 | 0 | 2 |
| Individualization of controlled ovarian stimulation in vitro fertilization using ovarian reserve markers | 31.7 | 0 | 2 |
| A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial | 31.7 | 0 | 2 |
| Effect of smoking on ovarian reserve and ovarian stimulation in in- vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| Genetics of gonadotropins and their receptors as markers of ovarian reserve and response in controlled ovarian stimulation | 31.7 | 0 | 2 |
| Comparison of serum anti-mullerian hormone among fertile and infertile normal and diminished ovarian reserve groups | 31.7 | 0 | 2 |
| What do reproductive-age women who undergo oocyte cryopreservation think about the process as a means to preserve fertility? | 31.7 | 0 | 2 |
| The case for aromatase inhibitors use in Oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in Breast Cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate | 31.7 | 0 | 2 |
| Low AMH levels as a marker of reduced ovarian reserve in young women affected by Down's syndrome. | 31.7 | 0 | 2 |
| A clinical dilemma: the potential use of egg freezing to preserve fertility in a young patient at risk of developing premature ovarian failure | 31.7 | 0 | 2 |
| Does controlled ovarian stimulation prior to chemotherapy increase primordial follicle loss and diminish ovarian reserve? An animal study | 31.7 | 0 | 2 |
| Catastrophic payment for assisted reproduction techniques with conventional ovarian stimulation in the public health sector of South Africa: frequency and coping strategies | 31.7 | 0 | 2 |
| Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma | 31.7 | 0 | 2 |
| Assessment of ovarian reserve based on hormonal parameters, ovarian volume, and antral follicle count in women with familial Mediterranean fever | 31.7 | 0 | 2 |
| Luteal‐phase ovarian stimulation vs conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: a large retrospective cohort study | 31.7 | 0 | 2 |
| Specific ranges of anti-Mullerian hormone and antral follicle count correlate to provide a prognostic indicator for IVF outcome | 31.7 | 0 | 2 |
| A survey of Irish consultants regarding awareness of sperm freezing and assisted reproduction. | 31.7 | 0 | 2 |
| Cycle-to-cycle variation in utero-ovarian hemodynamic indices in ovarian stimulation and natural cycles of the same women and its effect on the outcome of assisted reproduction treatment. | 31.7 | 0 | 2 |
| Comparing four ovarian reserve markers--associations with ovarian response and live births after assisted reproduction | 31.7 | 0 | 2 |
| Luteinizing hormone-releasing hormone agonists for ovarian stimulation in assisted reproduction | 31.7 | 0 | 2 |
| Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction | 31.7 | 0 | 2 |
| Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients. | 31.7 | 0 | 2 |
| Ovarian stimulation for assisted reproduction | 31.7 | 0 | 2 |
| Mole modifications following controlled ovarian stimulation for assisted reproduction technologies | 31.7 | 0 | 2 |
| Ovarian stimulation in assisted reproduction. | 31.7 | 0 | 2 |
| Embryo Cryopreservation Following In-Vitro Maturation for Fertility Preservation in a Woman with Mullerian Adenosarcoma: A Case Report | 31.7 | 0 | 2 |
| Oocyte vitrification for elective fertility preservation: lessons for patient counseling | 31.7 | 0 | 2 |
| FERTILITY PRESERVATION OF WOMEN: OOCYTE VITRIFICATION | 31.7 | 0 | 2 |
| Oocyte vitrification as an efficient option for elective fertility preservation | 31.7 | 0 | 2 |
| Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities for fertility preservation according to number of cryopreserved oocytes and age at retrieval | 31.7 | 0 | 2 |
| Obstetric outcome after oocyte vitrification and warming for fertility preservation in women with cancer. | 31.7 | 0 | 2 |
| The Russian experience of autotransplantation of vitrified ovarian tissue to a cancer patient | 31.7 | 0 | 2 |
| Practical clinical aspects of oocyte vitrification for fertility preservation | 31.7 | 0 | 2 |
| Five years' experience using oocyte vitrification to preserve fertility for medical and nonmedical indications | 31.7 | 0 | 2 |
| Oocyte vitrification in a single woman with diminished ovarian reserve resulting in live birth | 31.7 | 0 | 2 |
| Oocyte vitrification and its impact on the clinical practice of assisted reproduction | 31.7 | 0 | 2 |
| Effects of cryopreservation time and thawing method of human oocyte vitrification on the outcome of assisted reproduction | 31.7 | 0 | 2 |
| New options in assisted reproduction technology: the Cryotop method of oocyte vitrification | 31.7 | 0 | 2 |
| Serum AMH Level to Predict the Hyper Response in Women with PCOS and Non-PCOS Undergoing Controlled Ovarian Stimulation in ART | 31.7 | 0 | 2 |
| Preprogrammed, unmonitored ovarian stimulation reduces expense without compromising the outcome of assisted reproduction | 31.7 | 0 | 2 |
| Viability of cumulus cells is associated with basal AMH levels in assisted reproduction. | 31.7 | 0 | 2 |
| Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated with gonadotropin after pituitary suppression | 31.7 | 0 | 2 |
| Anti-Mullerian hormone is a better marker than inhibin B, follicle stimulating hormone, estradiol or antral follicle count in predicting the outcome of in vitro fertilization | 31.7 | 0 | 2 |
| Performance of different ovarian reserve markers for predicting the numbers of oocytes retrieved and mature oocytes | 31.7 | 0 | 2 |
| Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation | 31.7 | 0 | 2 |
| First French live-birth after oocyte vitrification performed before chemotherapy for fertility preservation | 31.7 | 0 | 2 |
| Serum anti-Mullerian hormone is a useful measure of quantitative ovarian reserve but does not predict the chances of live-birth pregnancy | 31.7 | 0 | 2 |
| Clinical Utility of Measurement of Anti-Müllerian Hormone in Reproductive Endocrinology | 31.7 | 0 | 2 |
| Do ovarian reserve tests predict miscarriage in women undergoing assisted reproduction treatment? | 31.7 | 0 | 2 |
| A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count | 31.7 | 0 | 2 |
| Myotonic dystrophy type 1 and PGD: ovarian stimulation response and correlation analysis between ovarian reserve and genotype | 31.7 | 0 | 2 |
| Ovarian stimulation and emergency in vitro fertilization for fertility preservation in cancer patients | 31.7 | 0 | 2 |
| Oocyte cryopreservation after controlled ovarian hyperstimulation in mosaic Turner syndrome: another fertility preservation option in a dedicated UK clinic | 31.7 | 0 | 2 |
| The cohort of antral follicles measuring 2-6 mm reflects the quantitative status of ovarian reserve as assessed by serum levels of anti-Müllerian hormone and response to controlled ovarian stimulation | 31.7 | 0 | 2 |
| Cystic fibrosis (cf) and ovarian reserve: A cross-sectional study examining serum anti-mullerian hormone (amh) in young women | 31.7 | 0 | 2 |
| Life after unsuccessful IVF treatment in an assisted reproduction unit: a qualitative analysis of gains through loss among Chinese persons in Hong Kong. | 31.7 | 0 | 2 |
| Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH. | 31.7 | 0 | 2 |
| Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation | 31.7 | 0 | 2 |
| LH serum levels during ovarian stimulation as predictors of ovarian response and assisted reproduction outcome in down-regulated women stimulated with recombinant FSH. | 31.7 | 0 | 2 |
| Concentrations of gonadotrophins and steroids in pre-ovulatory follicular fluid and serum in relation to stimulation protocol and outcome of assisted reproduction treatment | 31.7 | 0 | 2 |
| Is there any place for oocyte cryopreservation after cancer treatment? | 31.7 | 0 | 2 |
| Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study | 31.7 | 0 | 2 |
| Effect of pituitary downregulation on antral follicle count, ovarian volume and stromal blood flow measured by three-dimensional ultrasound with power Doppler prior to ovarian stimulation | 31.7 | 0 | 2 |
| Optimizing human oocyte cryopreservation for fertility preservation patients: should we mature then freeze or freeze then mature? | 31.7 | 0 | 2 |
| Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial | 31.7 | 0 | 2 |
| Preovulatory follicular fluid: relationships to ovarian stimulation protocol, fertilization, and sperm penetration in vitro | 31.7 | 0 | 2 |
| Anti-Müllerian hormone and antral follicle count for prediction of ovarian stimulation response in polycystic ovary syndrome. | 31.7 | 0 | 2 |
| Anti-mullerian hormone as a marker of ovarian reserve | 31.7 | 0 | 2 |
| Antral follicle count and FSH concentration after clomiphene citrate challenge test in the prediction of ovarian response during IVF treatment | 31.7 | 0 | 2 |
| Response to 'Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?'. | 31.7 | 0 | 2 |
| Anti-Mullerian hormone (AMH): what do we still need to know? | 31.7 | 0 | 2 |
| The Impact of Adnexal Torsion on Antral Follicle Count when Compared With Contralateral Ovary | 31.7 | 0 | 2 |
| Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure | 31.7 | 0 | 2 |
| A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation | 31.7 | 0 | 2 |
| Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer | 31.7 | 0 | 2 |
| Need for Comprehensive Counseling in Women Requesting Oocyte Cryopreservation | 31.7 | 0 | 2 |
| Ovarian stimulation for fertility preservation in patients with cancer | 31.7 | 0 | 2 |
| The effect of elevated progesterone levels before oocyte retrieval in women undergoing ovarian stimulation for IVF treatment on the genomic profile of peri-implantation endometrium. | 31.7 | 0 | 2 |
| Effective method for emergency fertility preservation: random-start controlled ovarian stimulation | 31.7 | 0 | 2 |
| Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation | 31.7 | 0 | 2 |
| Evolution of a reproductive endocrinologist: the Society for Reproductive Endocrinology and Infertility fellows retreat and preliminary results of manpower survey | 31.7 | 0 | 2 |
| Serum level of anti-mullerian hormone in early follicular phase as a predictor of ovarian reserve and pregnancy outcome in assisted reproductive technology cycles | 31.7 | 0 | 2 |
| Posthumous assisted reproduction: a survey of attitudes of couples seeking fertility treatment and the degree of agreement between intimate partners | 31.7 | 0 | 2 |
| Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study | 31.7 | 0 | 2 |
| Viral infections among couples for assisted reproduction in a fertility clinic in Nigeria. | 31.7 | 0 | 2 |
| Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy | 31.7 | 0 | 2 |
| Can highly sensitive antimüllerian hormone testing predict failed response to ovarian stimulation? | 31.7 | 0 | 2 |
| Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? | 31.7 | 0 | 2 |
| Idiopathic premature ovarian failure: what is the most suitable ovarian stimulation protocol? | 31.7 | 0 | 2 |
| The significance of antral follicle count in controlled ovarian stimulation and intrauterine insemination | 31.7 | 0 | 2 |
| Fertility preservation with ovarian stimulation protocols prior to cancer treatment | 31.7 | 0 | 2 |
| Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome | 31.7 | 0 | 2 |
| Menstrual cycle characteristics of young females with occult primary ovarian insufficiency at initial diagnosis and one-year follow-up with serum amh level and antral follicle count. | 31.7 | 0 | 2 |
| Age-related nomograms for antral follicle count and anti-Mullerian hormone for subfertile Chinese women in Singapore | 31.7 | 0 | 2 |
| Medical egg freezing: the importance of a patient-centered approach to fertility preservation | 31.7 | 0 | 2 |
| Medical egg freezing and cancer patients' hopes: Fertility preservation at the intersection of life and death | 31.7 | 0 | 2 |
| Oocyte Cryopreservation for Fertility Preservation in Healthy Women | 31.7 | 0 | 2 |
| Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss in younger in vitro fertilization patients | 31.7 | 0 | 2 |
| Knowledge, attitudes, and intentions toward fertility awareness and oocyte cryopreservation among obstetrics and gynecology resident physicians | 31.7 | 0 | 2 |
| Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy | 31.7 | 0 | 2 |
| Ovarian response to controlled ovarian stimulation for fertility preservation before oncology treatment: A retrospective cohort of 157 patients | 31.7 | 0 | 2 |
| The Impact of a Long-Acting Oral Sphingosine-1-Phosphate Analogue on Ovarian Aging in a Rat Model | 31.7 | 0 | 2 |
| Successful controlled ovarian stimulation despite elevated hCG levels after first-trimester abortion in the context of fertility preservation | 31.7 | 0 | 2 |
| Double ovarian stimulation (DuoStim) protocol for fertility preservation in female oncology patients | 31.7 | 0 | 2 |
| Hyperandrogenemia and ovarian reserve in patients with Mayer-Rokitansky-Küster-Hauser syndrome type 1 and 2: potential influences on ovarian stimulation. | 31.7 | 0 | 2 |
| The impact of ovarian stimulation protocol on oocyte quality, subsequent in vitro embryo development, and pregnancy after transfer to recipients in Eld's deer (Rucervus eldii thamin). | 31.7 | 0 | 2 |
| Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation. | 31.7 | 0 | 2 |
| Evaluation of Ovarian Reserve with AMH Level in Patients with Well-Differentiated Thyroid Cancer Receiving Radioactive Iodine Ablation Treatment | 31.7 | 0 | 2 |
| Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes | 31.7 | 0 | 2 |
| The impact of unilateral oophorectomy on ovarian reserve in assisted reproduction: a systematic review and meta-analysis | 31.7 | 0 | 2 |
| Assessment of ovarian reserve by antral follicle count in ovaries with endometrioma | 31.7 | 0 | 2 |
| Long-acting recombinant follicle-stimulating hormone in random-start ovarian stimulation protocols for fertility preservation in women with cancer | 31.7 | 0 | 2 |
| A specific controlled ovarian stimulation (COS) protocol for fertility preservation in women with breast cancer undergoing neoadjuvant chemotherapy | 31.7 | 0 | 2 |
| Predictive value of antral follicle count and serum anti-Müllerian hormone: Which is better for live birth prediction in patients aged over 40 with their first IVF treatment? | 31.7 | 0 | 2 |
| New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles | 31.7 | 0 | 2 |
| Do endometriomas grow during ovarian stimulation for assisted reproduction? A three-dimensional volume analysis before and after ovarian stimulation | 31.7 | 0 | 2 |
| Medical and elective fertility preservation: impact of removal of the experimental label from oocyte cryopreservation | 31.7 | 0 | 2 |
| Impact of vitamin D levels on ovarian reserve and ovarian response to ovarian stimulation in oocyte donors | 31.7 | 0 | 2 |
| Prediction value of anti-Mullerian hormone (AMH) serum levels and antral follicle count (AFC) in hormonal contraceptive (HC) users and non-HC users undergoing IVF-PGD treatment | 31.7 | 0 | 2 |
| The use of serum anti-Mullerian hormone (AMH) levels and antral follicle count (AFC) to predict the number of oocytes collected and availability of embryos for cryopreservation in IVF. | 31.7 | 0 | 2 |
| Association of a promoter polymorphism in FSHR with ovarian reserve and response to ovarian stimulation in women undergoing assisted reproductive treatment | 31.7 | 0 | 2 |
| Nondominant small follicles are a promising source of mature oocytes in modified natural cycle in vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation | 31.7 | 0 | 2 |
| Fertility Preservation Before Cancer Treatment: Options, Strategies, and Resources | 31.7 | 0 | 2 |
| Fertility Preservation Through Oocyte Cryopreservation in a Patient with Ovarian Dysgerminocarcinoma: A Case Report | 31.7 | 0 | 2 |
| BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles | 31.7 | 0 | 2 |
| Live birth following in vitro maturation of oocytes retrieved from extracorporeal ovarian tissue aspiration and embryo cryopreservation for 5 years | 31.7 | 0 | 2 |
| Ovarian stimulation for oocyte cryopreservation for prevention of age-related fertility loss: one in five is a low responder | 31.7 | 0 | 2 |
| Left Out in the Cold: Arguments Against Non-Medical Oocyte Cryopreservation | 31.7 | 0 | 2 |
| The dynamic changes of anti-Mullerian hormone and inhibin B during controlled ovarian hyperstimulation in decreased ovarian reserve women and the effect on clinical outcome | 31.7 | 0 | 2 |
| Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes | 31.7 | 0 | 2 |
| A single nucleotide polymorphism of bone morphogenic protein-15 is not associated with ovarian reserve or response to ovarian stimulation | 31.7 | 0 | 2 |
| Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET | 31.7 | 0 | 2 |
| Self-operated endovaginal telemonitoring versus traditional monitoring of ovarian stimulation in assisted reproduction: an RCT | 31.7 | 0 | 2 |
| Fertility preservation in a patient with benign multicystic peritoneal mesothelioma | 31.7 | 0 | 2 |
| An investigational ovarian stimulation protocol increased significantly the psychological burden in women with premature ovarian failure | 31.7 | 0 | 2 |
| Mild/minimal stimulation protocol for ovarian stimulation of patients at high risk of developing ovarian hyperstimulation syndrome | 31.7 | 0 | 2 |
| Evaluation of serum anti-Mullerian hormone levels to assess the ovarian reserve in women with severe endometriosis | 31.7 | 0 | 2 |
| What is the quality of information on social oocyte cryopreservation provided by websites of Society for Assisted Reproductive Technology member fertility clinics? | 31.7 | 0 | 2 |
| Dehydroepiandrosterone supplementation improves predictive markers for diminished ovarian reserve: serum AMH, inhibin B and antral follicle count | 31.7 | 0 | 2 |
| Prospective analysis of ovarian reserve markers as determinant in response to controlled ovarian stimulation in women undergoing IVF cycles in low resource setting in India | 31.7 | 0 | 2 |
| A prediction model to select PCOS patients suitable for IVM treatment based on anti-Mullerian hormone and antral follicle count. | 31.7 | 0 | 2 |
| Fertility preservation using controlled ovarian hyperstimulation and oocyte cryopreservation in a premenarcheal female with myelodysplastic syndrome | 31.7 | 0 | 2 |
| Fertility preservation utilizing controlled ovarian hyperstimulation and oocyte cryopreservation in a premenarcheal female with myelodysplastic syndrome | 31.7 | 0 | 2 |
| Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation | 31.7 | 0 | 2 |
| The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women. | 31.7 | 0 | 2 |
| Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve | 31.7 | 0 | 2 |
| The effect of laparoscopic ovarian cystectomy versus coagulation in bilateral endometriomas on ovarian reserve as determined by antral follicle count and ovarian volume: a prospective randomized study | 31.7 | 0 | 2 |
| Depot GnRH-agonist trigger for breast-cancer patient undergoing ovarian stimulation resulted in mature oocytes for cryopreservation: a case report | 31.7 | 0 | 2 |
| Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined. | 31.7 | 0 | 2 |
| G546A polymorphism of growth differentiation factor-9 contributes to the poor outcome of ovarian stimulation in women with diminished ovarian reserve. | 31.7 | 0 | 2 |
| Follicular-fluid anti-Mullerian hormone concentrations are predictive of assisted reproduction outcome in PCOS patients | 31.7 | 0 | 2 |
| Intermittent vaginal injections of gonadotrophins for ovarian stimulation in IVF treatment | 31.7 | 0 | 2 |
| Does 3D ultrasound offer any advantage in the pretreatment assessment of ovarian reserve and prediction of outcome after assisted reproduction treatment? | 31.7 | 0 | 2 |
| Oocyte cryopreservation as alternative to embryo cryopreservation - some pertinent ethical concerns | 31.7 | 0 | 2 |
| Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. On behalf of The Feronia and Apis study group | 31.7 | 0 | 2 |
| Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study | 31.7 | 0 | 2 |
| Limited ovarian stimulation results in the recovery of mature oocytes in polycystic ovarian disease patients: a preliminary report | 31.7 | 0 | 2 |
| Polycystic ovary syndrome patients as oocyte donors: the effect of ovarian stimulation protocol on the implantation rate of the recipient | 31.7 | 0 | 2 |
| A novel ovarian stimulation protocol for use with the assisted reproductive technologies | 31.7 | 0 | 2 |
| Growth hormone, oestradiol, progesterone and testosterone concentrations in follicular fluid after ovarian stimulation with various regimes for assisted reproduction | 31.7 | 0 | 2 |
| Relationship between serum anti-Mullerian hormone and intrafollicular AMH levels in PCOS women | 31.7 | 0 | 2 |
| Successful Ovarian Stimulation for Fertility Preservation in a Patient with Chronic Myeloid Leukemia: Switch from Nilotinib to Interferon-α. | 31.7 | 0 | 2 |
| Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study | 31.7 | 0 | 2 |
| Single embryo implantation per IVF cycle: the answer to every request for assisted reproduction? | 31.7 | 0 | 2 |
| Role of FSHR rs6165 and ESR2 rs4986938 polymorphisms in ovarian stimulation of Iranian women who underwent assisted reproduction treatment | 31.7 | 0 | 2 |
| Outcome of Oocyte Vitrification Combined with Microdissection Testicular Sperm Extraction and Aspiration for Assisted Reproduction in Men. | 31.7 | 0 | 2 |
| Costs of medically assisted reproduction treatment at specialized fertility clinics in the Danish public health care system: results from a 5-year follow-up cohort study | 31.7 | 0 | 2 |
| Comparative protein expression profiling in human cumulus cells in relation to oocyte fertilization and ovarian stimulation protocol | 31.7 | 0 | 2 |
| Use of serum inhibin B levels at the start of ovarian stimulation and at oocyte pickup in the prediction of assisted reproduction treatment outcome | 31.7 | 0 | 2 |
| Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction | 31.7 | 0 | 2 |
| Maternal menopause as a predictor of anti-Mullerian hormone level and antral follicle count in daughters during reproductive age. | 31.7 | 0 | 2 |
| Expectations for success in fertility treatment involving assisted reproduction | 31.7 | 0 | 2 |
| Annual report of Reproductive Endocrinology Committee, Japan Society of Obstetrics and Gynecology, 2013 | 31.7 | 0 | 2 |
| Clinical experience with an ovarian stimulation protocol for intrauterine insemination adopting a gonadotropin releasing hormone antagonist at low dose. | 31.7 | 0 | 2 |
| Evaluation of Ovarian Reserve Based on Hormonal Parameters, Ovarian Volume, and Antral Follicle Count in Women with Type 2 Diabetes Mellitus | 31.7 | 0 | 2 |
| With low ovarian reserve, Highly Individualized Egg Retrieval (HIER) improves IVF results by avoiding premature luteinization | 31.7 | 0 | 2 |
| Is there a need for recombinant human luteinizing hormone (lutropin alfa) supplementation in ovarian stimulation for assisted reproduction? | 31.7 | 0 | 2 |
| Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An ana | 31.7 | 0 | 2 |
| Selective early elimination of luteal support in assisted reproduction cycles using a gonadotropin-releasing hormone agonist during ovarian stimulation | 31.7 | 0 | 2 |
| Clinical effects of oocyte cryopreservation in assisted reproduction technology | 31.7 | 0 | 2 |
| Ovarian reserve evaluation by anti-mullerian hormone in women undergoing laparoscopic cystectomy of endometrioma | 31.7 | 0 | 2 |
| Ovarian reserve and response to stimulation in women undergoing fertility preservation according to malignancy type | 31.7 | 0 | 2 |
| Ultrasound-guided Retrieval of Mature Oocytes for Fertility Preservation During Laparoscopic Oophorectomy: A Case Report | 31.7 | 0 | 2 |
| Prospective assessment of follicular growth and the oocyte cohort after ovarian stimulation for fertility preservation in 90 cancer patients versus 180 matched controls | 31.7 | 0 | 2 |
| Update on fertility preservation from the Barcelona International Society for Fertility Preservation–ESHRE–ASRM 2015 expert meeting: indications, results and future perspectives†‡ | 31.7 | 0 | 2 |
| Systematic proposal of fertility preservation by mature oocyte cryopreservation for recurrent benign ovarian tumors | 31.7 | 0 | 2 |
| Multicenter evaluation of the Access AMH antimüllerian hormone assay for the prediction of antral follicle count and poor ovarian response to controlled ovarian stimulation | 31.7 | 0 | 2 |
| The use of anti-Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and -counseling | 31.7 | 0 | 2 |
| Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors? | 31.7 | 0 | 2 |
| DHEA use to improve likelihood of IVF/ICSI success in patients with diminished ovarian reserve: A systematic review and meta-analysis | 31.7 | 0 | 2 |
| Is tissue factor pathway inhibitor a marker of procoagulable status in healthy infertile women undergoing ovarian stimulation for assisted reproduction? | 31.7 | 0 | 2 |
| Specific protocols of controlled ovarian stimulation for oocyte cryopreservation in breast cancer patients | 31.7 | 0 | 2 |
| Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis | 31.7 | 0 | 2 |
| Egg freezing for fertility preservation and family planning: a nationwide survey of US Obstetrics and Gynecology residents | 31.7 | 0 | 2 |
| La cryopréservation ovocytaire va-t-elle relancer l’intérêt du prélèvement chirurgical de spermatozoïdes synchrone du recueil ovocytaire en cas d’azoospermie non obstructive ? | 31.7 | 0 | 2 |
| Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman’s age and markers of ovarian reserve | 31.7 | 0 | 2 |
| Fertility preservation in women with malignancies: the accuracy of antral follicle count collected randomly during the menstrual cycle in predicting the number of oocytes retrieved | 31.7 | 0 | 2 |
| Limited importance of pre-embryo pronuclear morphology (zygote score) in assisted reproduction outcome in the absence of embryo cryopreservation | 31.7 | 0 | 2 |
| Comparison of 2 Ovarian Stimulation Protocols for Women With Low Ovarian Reserve | 31.7 | 0 | 2 |
| Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle | 31.7 | 0 | 2 |
| Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients | 31.7 | 0 | 2 |
| Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF | 31.7 | 0 | 2 |
| Can anti-Mullerian hormone (AMH) predict the outcome of intrauterine insemination with controlled ovarian stimulation? | 31.7 | 0 | 2 |
| Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression | 31.7 | 0 | 2 |
| Effect of Oocyte Vitrification on Fertilization Rate, Embryo Quality and Development | 31.7 | 0 | 2 |
| Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART) | 31.7 | 0 | 2 |
| Oocyte Cryopreservation | 31.7 | 0 | 2 |
| Anti-mullerian Hormone (AMH) After Treatment of Endometriomas With Alcohol Sclerotherapy Versus Surgery: Clinical Trial | 31.7 | 0 | 2 |
| Interest of Automated Oocyte Freezing | 31.7 | 0 | 2 |
| Anti-Mullerian Hormone (AMH) is a Marker for Ovarian Reserve. There Are Many Studies About AMH Changes in Ovarian Surgery, But Little is Known for Other Surgeries. We Seek to Investigate the Hormone Variations Before and After Uterine Artey Liga | 31.7 | 0 | 2 |
| Evaluation of Anti-mullerian Hormone Levels as Predictive of IVF Outcomes in Women Over 38 Years Old | 31.7 | 0 | 2 |
| A Novel Stimulation Protocol and the Conventional Low Dose Step-up and Step Down Regimens | 31.7 | 0 | 2 |
| A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follic | 31.7 | 0 | 2 |
| What advice should we give our patients to preserve their fertility and avoid needing oocyte donation in the future? - A Social Fertility Preservation program | 31.7 | 0 | 2 |
| Oocyte cryopreservation for future fertility: comparison of ovarian response between cancer and non-cancer patients | 31.7 | 0 | 2 |
| Safety data for the use of nasal human menopausal gonadotropins: a potential novel approach for fertility treatment | 31.7 | 0 | 2 |
| Double Pick up in Poor Prognosis Women | 31.7 | 0 | 2 |
| Comparison of the Number of Oocytes Obtained Between Chinese and Caucasian Women in IVF Treatment | 31.7 | 0 | 2 |
| Administration of DHEA in Patients With Poor Response to Ovarian Stimulation for IVF | 31.7 | 0 | 2 |
| Random-start ovarian stimulation with aromatase inhibitor for fertility preservation in women with Japanese breast cancer | 31.7 | 0 | 2 |
| IVF Hyper-responders: Oocyte Vitrification Compared With Embryo Freezing | 31.7 | 0 | 2 |
| Oocyte Cryopreservation Study (Egg Banking) | 31.7 | 0 | 2 |
| Biomarkers of Ovarian Reserve and Correlation With IVF Treatments | 31.7 | 0 | 2 |
| Levels of Anti-Mullerian Hormone (AMH) During Ovarian Stimulation With Gonadotropins | 31.7 | 0 | 2 |
| Clomiphene Citrate in Combination With Gonadotropins for Ovarian Stimulation in Women With Poor Ovarian Response. | 31.7 | 0 | 2 |
| The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol | 31.7 | 0 | 2 |
| Efficacy of Ovarian Stimulation Based on FSHR Genotype Status | 31.7 | 0 | 2 |
| Fertility Preservation by Ovarian and Oocyte Cryopreservation | 31.7 | 0 | 2 |
| Anti-müllerian Hormone for the Prediction of Ovarian Response in Progestin-Primed Ovarian Stimulation Protocol for IVF. | 31.7 | 0 | 2 |
| The Application of a New Ovarian Stimulation Protocol in IVF | 31.7 | 0 | 2 |
| Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve | 31.7 | 0 | 2 |
| Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist | 31.7 | 0 | 2 |
| Use of Dehydroepiandrosterone (DHEA) in Women With Normal and Poor Ovarian Reserve Undergoing IVF | 31.7 | 0 | 2 |
| Individualization of Ovarian Stimulation Using AMH Maximizes the Benefits and Minimizes Complications and Risks | 31.7 | 0 | 2 |
| Effect of Follicular Phase Acupuncture on Anti-Mullerian Hormone in Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF And The Effect on Assisted Reproduction Outcome | 31.7 | 0 | 2 |
| Antimullerian Hormone in Endometriomas | 31.7 | 0 | 2 |
| Fertility Preservation in Breast Cancer Patients | 31.7 | 0 | 2 |
| Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment | 31.7 | 0 | 2 |
| Evaluating the AMH Levels During Natural Cycle | 31.7 | 0 | 2 |
| Antimullerian Hormone Versus Antral Follicle Count for Determination of Gonadotrophin Dosing in IVF | 31.7 | 0 | 2 |
| Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients | 31.7 | 0 | 2 |
| Ovarian stimulation protocol for in vitro fertilization with gonadotropin-releasing hormone agonist widens the implantation window | 31.7 | 0 | 2 |
| Choice of an ovarian stimulation protocol according to the follicular puncture method in an in vitro fertilization programme | 31.7 | 0 | 2 |
| The functional ovarian reserve in assisted reproduction. A clinical dilemma | 31.7 | 0 | 2 |
| Sonographically monitored ovarian stimulation for assisted reproduction: a prospective, blind study | 31.7 | 0 | 2 |
| Ovarian stimulation protocol and the outcome of in vitro fertilization are not related to the ability of follicular fluid to induce sperm acrosome reaction | 31.7 | 0 | 2 |
| Luteinizing hormone (LH) surge in patients using buserelin spray during ovarian stimulation for assisted reproduction | 31.7 | 0 | 2 |
| Serum oestradiol and progesterone concentrations during prolonged coasting in 15 women at risk of ovarian hyperstimulation syndrome following ovarian stimulation for assisted reproduction treatment | 31.7 | 0 | 2 |
| Recombinant versus urinary FSH for ovarian stimulation in assisted reproduction | 31.7 | 0 | 2 |
| Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation | 31.7 | 0 | 2 |
| Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction | 31.7 | 0 | 2 |
| Follitropin-alfa for ovarian stimulation during assisted reproduction treatment: a national collaborative study | 31.7 | 0 | 2 |
| Ovarian Reserve and Ankylosing Spondylitis | 31.7 | 0 | 2 |
| Measurement of anti-mullerian hormone by Beckman Coulter ELISA and DSL ELISA in assisted reproduction: differences between serum and follicular fluid | 31.7 | 0 | 2 |
| Assisted reproduction in male cancer survivors: fertility treatment and outcome in 67 couples | 31.7 | 0 | 2 |
| Antral follicle count in clinical practice: building the bridge from ovarian reserve to in vitro fertilization outcome | 31.7 | 0 | 2 |
| Prediction of ovarian reserve, poor response and pregnancy outcome based on basal antral follicle count and age in patients undergoing in vitro fertilization-embryo transfer | 31.7 | 0 | 2 |
| Results after assisted reproduction at a public fertility clinic | 31.7 | 0 | 2 |
| Reproductive endocrinology: vitamin D and AMH levels are correlated in human adults | 31.7 | 0 | 2 |
| Female fertility preservation: feasibility of emergency IVF for embryo freezing | 31.7 | 0 | 2 |
| Strategies for hormonal ovarian stimulation in IVF, based on materials of the centre for assisted reproduction "varna" | 31.7 | 0 | 2 |
| Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum anti‐Müllerian hormone and small antral follicle count using three‐dimensional ultrasound | 31.7 | 0 | 2 |
| Serum anti-Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan | 31.7 | 0 | 2 |
| Reply: Endometrioma excision and ovarian reserve: do assessments by antral follicle count and anti-Müllerian hormone yield contradictory results? | 31.7 | 0 | 2 |
| Endometrioma excision and ovarian reserve; do assessments by antral follicle count and anti-Müllerian hormone yield contradictory results? | 31.7 | 0 | 2 |
| Ovarian reserve and anti-Mullerian hormone (AMH) in mothers of dizygotic twins | 31.7 | 0 | 2 |
| Comparing the Effect of Laparoscopic Supracervical and Total Hysterectomy for Uterine Fibroids on Ovarian Reserve by Assessing Serum Anti-Mullerian Hormone Levels: A Prospective Cohort Study | 31.7 | 0 | 2 |
| The effect of isotretinoin on ovarian reserve based on hormonal parameters, ovarian volume, and antral follicle count in women with acne | 31.7 | 0 | 2 |
| Role of ovarian reserve markers, antimüllerian hormone and antral follicle count, as aneuploidy markers in ongoing pregnancies and miscarriages | 31.7 | 0 | 2 |
| Follicle-Stimulating Hormone/Luteinizing Hormone Ratio as an Independent Predictor of Response to Controlled Ovarian Stimulation | 31.7 | 0 | 2 |
| The effect of premature luteinizing hormone increases among high ovarian responders undergoing a gonadotropin-releasing hormone antagonist ovarian stimulation protocol | 31.7 | 0 | 2 |
| Usefulness of individualized FSH, LH and GH dosing in ovarian stimulation of women with low ovarian reserve | 31.7 | 0 | 2 |
| Evaluation of ovarian reserve using anti-müllerian hormone and antral follicle count in Sjögren's syndrome: Preliminary study | 31.7 | 0 | 2 |
| The use of autologous platelet-rich plasma (PRP) versus no intervention in women with low ovarian reserve undergoing fertility treatment: a non-randomized interventional study | 31.7 | 0 | 2 |
| Fertility Preservation Before Deployment: Oocyte and Sperm Freezing in Members of the Active Duty Military | 31.7 | 0 | 2 |
| Outcomes of fertility preservation in women with endometriosis: comparison of progestin-primed ovarian stimulation versus antagonist protocols | 31.7 | 0 | 2 |
| Oncologic oocyte cryopreservation: national comparison of fertility preservation between women with and without cancer | 31.7 | 0 | 2 |
| Live birth rate comparison of three controlled ovarian stimulation protocols for in vitro fertilization-embryo transfer in patients with diminished ovarian reserve after endometrioma cystectomy: a retrospective study | 31.7 | 0 | 2 |
| Ovarian stimulation for fertility preservation in women diagnosed with cancer | 31.7 | 0 | 2 |
| The impact of malignancy on response to ovarian stimulation for fertility preservation: a meta-analysis | 31.7 | 0 | 2 |
| Serum anti-Mullerian hormone (AMH) concentration has limited prognostic value for density of primordial and primary follicles, questioning it as an accurate parameter for the ovarian reserve | 31.7 | 0 | 2 |
| Outcomes of ovarian stimulation and fertility preservation in breast cancer patients with different hormonal receptor profiles | 31.7 | 0 | 2 |
| Oocyte vitrification for fertility preservation in women with endometriosis: an observational study | 31.7 | 0 | 2 |
| Ovarian stimulation for oocyte vitrification does not modify disease-free survival and overall survival rates in patients with early breast cancer | 31.7 | 0 | 2 |
| Mild stimulation protocol vs conventional controlled ovarian stimulation protocol in poor ovarian response patients: a prospective randomized controlled trial | 31.7 | 0 | 2 |
| The effect of acupuncture on anti-mullerian hormone and assisted reproduction outcome in Polycystic Ovary Syndrome patients undergoing in vitro fertilization | 31.7 | 0 | 2 |
| Effect of Progestin-primed Ovarian Stimulation Protocol on Outcomes of Aged Infertile Women Who Failed to Get Pregnant in the First IVF/ ICSI Cycle: A Self-controlled Study | 31.7 | 0 | 2 |
| Outcome of ovarian stimulation for oocyte cryopreservation in women with Turner syndrome | 31.7 | 0 | 2 |
| Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients | 31.7 | 0 | 2 |
| Optimal Ovulation Trigger-Oocyte Pickup Interval in Progestin-Primed Ovarian Stimulation Protocol: A Retrospective Study Using Propensity Score Matching | 31.7 | 0 | 2 |
| Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response | 31.7 | 0 | 2 |
| Vaginal cuff dehiscence following controlled ovarian stimulation recognized during egg retrieval | 31.7 | 0 | 2 |
| Defining thresholds for abnormal premature progesterone levels during ovarian stimulation for assisted reproduction technologies | 31.7 | 0 | 2 |
| The ethics of fertility treatment for same-sex male couples: Considerations for a modern fertility clinic | 31.7 | 0 | 2 |
| Expression of the anti-Mullerian hormone, kisspeptin 1, and kisspeptin 1 receptor in polycystic ovary syndrome and controlled ovarian stimulation rat models | 31.7 | 0 | 2 |
| The impact of the localisation of endometriosis lesions on ovarian reserve and assisted reproduction techniques outcomes | 31.7 | 0 | 2 |
| Combination Treatment of Preoperative Embryo Cryopreservation and Endoscopic Surgery (Surgery-ART Hybrid Therapy) in Infertile Women with Diminished Ovarian Reserve and Uterine Myomas or Ovarian Endometriomas | 31.7 | 0 | 2 |
| Risk factors for inadequate response to ovarian stimulation in assisted reproduction cycles: systematic review | 31.7 | 0 | 2 |
| Ovarian stimulation is a safe and effective fertility preservation option in the adolescent and young adult population | 31.7 | 0 | 2 |
| Conservative treatment versus surgical excision of ovarian dermoid cysts: Impact on ovarian stimulation and IVF cycle success | 31.7 | 0 | 2 |
| Oocyte cryopreservation for fertility preservation in women with ovarian endometriosis | 31.7 | 0 | 2 |
| EUropean REcommendations for female FERtility preservation (EU-REFER): A joint collaboration between oncologists and fertility specialists | 31.7 | 0 | 2 |
| Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study | 31.7 | 0 | 2 |
| Comparison of two different oocyte vitrification methods: a prospective, paired study on the same genetic background and stimulation protocol | 31.7 | 0 | 2 |
| Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer | 31.7 | 0 | 2 |
| Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology | 31.7 | 0 | 2 |
| Ovarian reserve parameters and response to controlled ovarian stimulation in infertile patients | 31.7 | 0 | 2 |
| Use of Growth Hormone in the IVF Treatment of Women With Poor Ovarian Reserve | 31.7 | 0 | 2 |
| Exposure to Fine Particulate Matter and Ovarian Reserve Among Women from a Fertility Clinic | 31.7 | 0 | 2 |
| Ovarian stimulation and egg retrieval in the acutely ill patient: special considerations | 31.7 | 0 | 2 |
| Elective egg freezing and male support: a qualitative study of men's roles in women's fertility preservation | 31.7 | 0 | 2 |
| Low Dose Growth Hormone Adjuvant Treatment With Ultra-Long Ovarian Stimulation Protocol in Poor Responders Showed Non-inferior Pregnancy Outcome Compared With Normal Responders | 31.7 | 0 | 2 |
| A novel de novo partial xq duplication in a girl with short stature, nonverbal learning disability and diminished ovarian reserve - effect of growth hormone treatment and fertility preservation strategies: a case report and up-to-date review | 31.7 | 0 | 2 |
| Investigating the effect of lifestyle risk factors upon number of aspirated and mature oocytes in in vitro fertilization cycles: Interaction with antral follicle count | 31.7 | 0 | 2 |
| Effect of Switching from a Progestin-Primed Ovarian Stimulation Protocol to a Modified Ultra-Long Protocol Among Women Who Had 1 Progestin-Primed Ovarian Stimulation (PPOS) Failure Verses Those Who Had 2 PPOS Failures | 31.7 | 0 | 2 |
| Ovarian stimulation for fertility preservation or family building in a cohort of transgender men | 31.7 | 0 | 2 |
| Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin-primed ovarian stimulation protocol for IVF: a retrospective cohort study | 31.7 | 0 | 2 |
| Progestin-primed ovarian stimulation improves the outcomes of IVF/ICSI cycles in infertile women with diminished ovarian reserve | 31.7 | 0 | 2 |
| Transvaginal ovarian drilling followed by controlled ovarian stimulation from the next day improves ovarian response for the poor responders with polycystic ovary syndrome during IVF treatment: a pilot study | 31.7 | 0 | 2 |
| SUN-266 Anti-Mullerian Hormone as a Marker of Ovarian Reserve in Female Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation | 31.7 | 0 | 2 |
| OR11-3 Evidence for Preserved Ovarian Reserve in Transgender Men Receiving Testosterone Therapy: Anti-Mullerian Hormone Serum Levels Decrease Modestly after One Year of Treatment | 31.7 | 0 | 2 |
| Intraindividual Embryo Morphokinetics Are Not Affected by a Switch of the Ovarian Stimulation Protocol Between GnRH Agonist vs. Antagonist Regimens in Consecutive Cycles | 31.7 | 0 | 2 |
| [INFLUENCE OF STIMULATION PROTOCOL ON MATURITY AND MORPHOLOGICAL FEATURES OF OOCYTES IN PATIENTS WITH LOW OVARIAN RESERVE: STUDY OF 72 IVF/ICSI TREATMENT CYCLES] | 31.7 | 0 | 2 |
| Level of AMH as a predictor of the result of ovarian stimulation | 31.7 | 0 | 2 |
| Ovarian stimulation after dehydroepiandrosterone supplementation in poor ovarian reserve: a randomized clinical trial | 31.7 | 0 | 2 |
| Impact of ABVD chemotherapy on ovarian reserve after fertility preservation in reproductive-aged women with Hodgkin lymphoma | 31.7 | 0 | 2 |
| Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response | 31.7 | 0 | 2 |
| Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A | 31.7 | 0 | 2 |
| Attitudes and experiences of health care professionals when caring for transgender men undergoing fertility preservation by egg freezing: a qualitative study | 31.7 | 0 | 2 |
| Delay in IVF treatment up to 180 days does not affect pregnancy outcomes in women with diminished ovarian reserve | 31.7 | 0 | 2 |
| Validating the Use of Corifollitropin Alfa in Progestin-Primed Ovarian Stimulation Protocol on Normal and High Responders by Comparing with Conventional Antagonist Protocol: A Retrospective Study | 31.7 | 0 | 2 |
| How fixed versus variable gonadotropin dose during controlled ovarian stimulation could influence the management of infertility patients undergoing IVF treatment: a national Delphi consensus | 31.7 | 0 | 2 |
| The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation | 31.7 | 0 | 2 |
| The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol | 31.7 | 0 | 2 |
| Importance of early and precise ascertainment of mosaic Turner syndrome for fertility preservation and assisted reproduction counseling | 31.7 | 0 | 2 |
| The quality of information about elective oocyte cryopreservation (EOC) on Australian fertility clinic websites | 31.7 | 0 | 2 |
| Anti-Müllerian hormone and antral follicle count differ in their ability to predict cumulative treatment outcomes of the first complete ovarian stimulation cycle in patients from POSEIDON groups 3 and 4 | 31.7 | 0 | 2 |
| Dietary patterns and ovarian reserve among women attending a fertility clinic | 31.7 | 0 | 2 |
| Is serum anti-Müllerian hormone (AMH) assay a satisfactory measure for ovarian reserve estimation? A comparison of serum and peritoneal fluid AMH levels | 31.7 | 0 | 2 |
| Differences in perceived stress during ovarian stimulation between women with infertility and those pursing oocyte cryopreservation | 31.7 | 0 | 2 |
| The indication for fertility preservation in women with Turner syndrome should not only be based on the ovarian reserve but also on the genotype and expected future health status | 31.7 | 0 | 2 |
| The comparison of evaluative effectiveness between antral follicle count/age ratio and ovarian response prediction index for the ovarian reserve and response functions in infertile women | 31.7 | 0 | 2 |
| Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis | 31.7 | 0 | 2 |
| Double-in vitro maturation increases the number of vitrified oocytes available for fertility preservation when ovarian stimulation is unfeasible | 31.7 | 0 | 2 |
| Is intrauterine insemination a viable treatment option for women over 43 years old? An analysis by ovarian stimulation protocol and sperm source | 31.7 | 0 | 2 |
| The effect of selenium and vitamin E supplementation on anti-Mullerian hormone and antral follicle count in infertile women with occult premature ovarian insufficiency: A randomized controlled clinical trial | 31.7 | 0 | 2 |
| Effect of a dual trigger on oocyte maturation in young women with decreased ovarian reserve for the purpose of elective oocyte cryopreservation | 31.7 | 0 | 2 |
| Comparison of a progestin-primed ovarian stimulation protocol with a flexible GnRH antagonist protocol in patients with polycystic ovary syndrome who are participating in an IVF programme: study protocol for a randomised controlled trial | 31.7 | 0 | 2 |
| The marketing of elective egg freezing: A content, cost and quality analysis of UK fertility clinic websites | 31.7 | 0 | 2 |
| An in silico model using prognostic genetic factors for ovarian response in controlled ovarian stimulation: A systematic review | 31.7 | 0 | 2 |
| Planned oocyte cryopreservation for fertility preservation | 31.7 | 0 | 2 |
| A Federated Blockchain Approach for Fertility Preservation and Assisted Reproduction in Smart Cities | 31.7 | 0 | 2 |
| Fertility Preservation for Adolescent and Young Adult Transmen: A Case Series and Insights on Oocyte Cryopreservation | 31.7 | 0 | 2 |
| Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger? | 31.7 | 0 | 2 |
| Impact of Laparoscopic Ovarian Drilling on Ovarian Reserve in Patients With Anovulatory Polycystic Ovarian Syndrome | 31.7 | 0 | 2 |
| Anti-Mullerian Hormone as a Marker of Ovarian Reserve and Function | 31.7 | 0 | 2 |
| Urinary Triclosan Concentrations and Diminished Ovarian Reserve among Women from a Fertility Clinic | 31.7 | 0 | 2 |
| A 5-year analysis of demographics, cycle characteristics and reproductive outcomes of 907 egg freezing cycles in patients with diminished ovarian reserve and age-related fertility decline | 31.7 | 0 | 2 |
| Physicians should avoid changing a patient’s ovarian stimulation protocol for the purpose of improving laboratory outcomes | 31.7 | 0 | 2 |
| Use of luteinizing hormone supplementation for ovarian stimulation in IVF/ICSI cycles of women with good ovarian reserve | 31.7 | 0 | 2 |
| A novel flexible progestin primed ovarian stimulation protocol: comparison of pregnancy outcomes with the flexible GnRH antagonist protocol in an oocyte donation program | 31.7 | 0 | 2 |
| Oncologic oocyte cryopreservation for fertility preservation: national trends and comparison of cycle characteristics between women with and without cancer | 31.7 | 0 | 2 |
| Elective egg freezing and male support: a qualitative study of men’s hidden roles in women’s fertility preservation | 31.7 | 0 | 2 |
| Does myotonic dystrophy affect ovarian reserve, response to controlled ovarian stimulation and ivf-preimplantation genetic diagnosis outcome in female patients? | 31.7 | 0 | 2 |
| Selective Discontinuation of Luteal Phase Support in Assisted Reproduction Cycles Using a Gonadotropin-Releasing Hormone Agonist and Human Menopausal Gonadotropins for Ovarian Stimulation | 31.7 | 0 | 2 |
| Recent Advances in Reproductive Endocrinology: Implications for Fertility Treatment in Gynecology | 31.7 | 0 | 2 |
| Anti-mullerian hormone and antral follicle count in polycystic ovary syndrome and non-polycystic ovary syndrome women | 31.7 | 0 | 2 |
| Impacts of endometrioma type and two-different techniques of laparoscopic cystectomyon ovarian reserve by measuring anti-mullerian hormone concentration | 31.7 | 0 | 2 |
| Studying the Effect of Laparoscopic Ovarian Drilling on Ovarian Reserve via Measurement of Anti-Mullerian Hormone in Polycystic Ovarian Syndrome Patients | 31.7 | 0 | 2 |
| 106 Effect of Heat-Stress on Antral Follicle Count and Serum Concentration of Anti-Mullerian Hormone in Bos taurus Crossbred Beef Cows | 31.7 | 0 | 2 |
| Recombinant FSH dosing during controlled ovarian stimulation in IVF treatment | 31.7 | 0 | 2 |
| The relevance of antral follicle count (AFC) as a marker of ovarian reserve in normal and infertile women in a tertiary care centre in Central India | 31.7 | 0 | 2 |
| Impact of the Duration of Controlled Ovarian Stimulation on Assisted Reproduction Cycle Outcomes | 31.7 | 0 | 2 |
| Ovarian stimulation is a safe and effective fertility preservation (FP) option in the adolescent population | 31.7 | 0 | 2 |
| Egg freezing for fertility preservation and family planning: a survey of OB/GYN residents across united states | 31.7 | 0 | 2 |
| Random start versus conventional start controlled ovarian stimulation in women with cancer: comparing oocyte yield among fertility preservation cycles | 31.7 | 0 | 2 |
| Day 6 blastocysts have higher aneuploidy rates compared to day 5 blastocyts after standardized controlled ovarian stimulation protocol | 31.7 | 0 | 2 |
| impact of breast cancer prognostic factors on the response to controlled ovarian stimulation patients undergoing fertility preservation | 31.7 | 0 | 2 |
| Is ovarian reserve and reproductive outcome compromised in breast cancer patients? experience in 1000 women undergoing fertility preservation (FP) | 31.7 | 0 | 2 |
| Ovarian reserve tests are associated with the number of oocytes matured in vitro and with the primordial follicle density in a population of candidates for fertility preservation | 31.7 | 0 | 2 |
| Intracytoplasmic Sperm Injection Outcome in Patient at Risk of Poor Responder Using Mild Ovarian Stimulation Protocol versus Short Gonadotropin Releasing Hormone Agonist Protocol | 31.7 | 0 | 2 |
| Antral Follicle Count versus Basal Follicle Stimulating Hormone as Predictors of Ovarian Response in Women Undergoing Superovulation with Long Protocol for Assisted Reproduction | 31.7 | 0 | 2 |
| Q135289054 | 31.7 | 0 | 2 |
| Q137191222 | 31.7 | 0 | 2 |
| Cyprus Fertina IVF Clinic | 31.7 | 0 | 2 |
| planned oocyte cryopreservation | 31.7 | 0 | 2 |
| double ovarian stimulation | 31.7 | 0 | 2 |
| GYN-FIV a.s. | 31.7 | 0 | 2 |
| Journal of High Energy Physics | 21.4 | 1 | 0 |
| Journal of Archaeological Science | 21.4 | 1 | 0 |
| Boston University | 21.4 | 1 | 0 |
| TERRIERS | 21.4 | 1 | 0 |
| National Center for Biotechnology Information | 21.4 | 1 | 0 |
| Information Processing Letters | 21.4 | 1 | 0 |
| Journal of the American Medical Informatics Association | 21.4 | 1 | 0 |
| Journal of Grid Computing | 21.4 | 1 | 0 |
| Natural Computing | 21.4 | 1 | 0 |
| Q180686 | 21.4 | 1 | 0 |
| Journal of Business Economics | 21.4 | 1 | 0 |
| Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen | 21.4 | 1 | 0 |
| European Food Research and Technology | 21.4 | 1 | 0 |
| Zeitschrift für Physik | 21.4 | 1 | 0 |
| Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie | 21.4 | 1 | 0 |